Jeffrey S Loutit

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

Scott J. Hecker, K. Raja Reddy, Maxim Totrov et al. · Journal of Medicinal Chemistry · 2015 · 405 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects

Eric Wenzler, Mark H. Gotfried, Jeffrey S Loutit et al. · Antimicrobial Agents and Chemotherapy · 2015 · 114 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +15

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

George H. Talbot, Anita Das, Stephanie S. Cush et al. · The Journal of Infectious Diseases · 2018 · 74 citations · Full text

Medicine, Infectious Diseases, Clinical Epidemiology +14

Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Gerald J. Fetterly, Christine M. Ong, Sujata M. Bhavnani et al. · Antimicrobial Agents and Chemotherapy · 2004 · 69 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with <i>Staphylococcus aureus</i> Bacteremia

Sujata M. Bhavnani, Julie Passarell, Joel Owen et al. · Antimicrobial Agents and Chemotherapy · 2006 · 58 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17